He Fought Claims of Harm From Infant Formula. Now He Regulates It.
Posted inAppointments and Executive Changes Babies and Infants Conflicts of Interest Ethics and Official Misconduct Food Food and Drug Administration Infant Formulas Jones Day Kyle Diamantas Necrotizing Enterocolitis Premature Babies Regulation and Deregulation of Industry Suits and Litigation (Civil) United States Politics and Government

He Fought Claims of Harm From Infant Formula. Now He Regulates It.

Kyle Diamantas, a former corporate lawyer, is the new director for the F.D.A. food division, which oversees infant formula. He defended a top maker in cases claiming the company had not warned of potential risks to very low-weight babies.
FDA Staffed Up to Review AI and Food Safety. Those Hires Are Now Gone.
Posted inArtificial Intelligence Califf, Robert M Diabetes Food Food and Drug Administration Food Contamination and Poisoning Government Employees Health and Human Services Department Hiring and Promotion Innovation Kennedy, Robert F Jr Layoffs and Job Reductions Medical Devices Presidential Transition (US) Regulation and Deregulation of Industry Robots and Robotics Tests (Medical) Trump, Donald J United States Politics and Government Wages and Salaries

FDA Staffed Up to Review AI and Food Safety. Those Hires Are Now Gone.

Teams evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though industry fees, not taxpayers, financed the employee salaries.
How an Activist Group Helped Torpedo MDMA Therapy
Posted inClinical Trials Drugs (Pharmaceuticals) Ethics and Official Misconduct Food and Drug Administration Institute for Clinical and Economic Review Lykos Therapeutics Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Psymposia Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

How an Activist Group Helped Torpedo MDMA Therapy

The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.